Ofatumumab with or without Bendamustine for Patients with Mantle Cell Lymphoma Who Cannot Have an Autologous Stem Cell Transplant

Full Title

Ofatumumab With or Without Bendamustine for Patients with Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant


Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) that can be challenging to treat. One approach is to combine an antibody against the tumor with a chemotherapy drug. In this study, researchers are evaluating the used of the antibody ofatumumab and the chemotherapy drug bendamustine for patients with previously untreated MCL who cannot have an autologous stem cell transplant.

Ofatumumab is approved for treating chronic lymphocytic leukemia (CLL). Bendamustine is approved for treating CLL and slow-growing NHL. Their use in this study is considered investigational. Patients will receive ofatumumab alone or with bendamustine, depending upon their initial risk profile.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have previously untreated MCL.
  • Patients must be age 65 or older, or be over 18 and ineligible for an autologous stem cell transplant.

For more information and to see if you are eligible for this study, please contact Dr. Paul A. Hamlin at 212-639-6143.





Disease Status

Newly Diagnosed



Zelenetz, Andrew, MD, PhD